|

Fenretinide Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: 4-HPR, N-(4-hydroxyphenyl)-all-trans-retinamide, N-(4-hydroxyphenyl)retinamide, ST-001, nanoFenretinide

Pipeline

Phase 1: 2

Top Sponsors

  • SciTech Development, Inc.2

Indications

  • Cancer2
  • Sézary's Disease1
  • Cutaneous T-Cell Lymphoma, Unspecified1
  • Peripheral T-Cell Lymphoma, Not Classified1
  • Cutaneous/Peripheral T-Cell Lymphoma1

Scottsdale, Arizona1 trial

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

Mayo Clinic Arizona

Phase 1

Los Angles, California1 trial

ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer

University of Southern California

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.